AxoGen Saham

AxoGen EBITDA

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari AxoGen (AXGN) pada 16 Agu 2026 adalah -7,85 Juta. USD. Tahun sebelumnya, EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah -1,76 Juta. USD — perubahan sebesar 346,47% (lebih rendah).

EBITDA

-7,85 Juta.USD

YoY

346,47%

Terakhir Diperbarui:

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari AxoGen adalah 2026 -7,85 Juta. USD. EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari AxoGen adalah 2025 -1,76 Juta. USD. Menurun 346,47% lebih rendah dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

AxoGen Analisis saham

Apa yang dilakukan AxoGen? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham AxoGen

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) AxoGen adalah -7,85 Juta. USD pada tahun 2026.

EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) dari AxoGen berubah dari -1,76 Juta. USD menjadi -7,85 Juta. USD, mewakili perubahan 346,47%. Nilainya lebih rendah daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) AxoGen sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

EBITDA mengukur kinerja operasional sebelum dampak struktur keuangan, lingkungan pajak, dan biaya penyusutan non-kas.

EBITDA = EBIT + Penyusutan & Amortisasi

USD EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) adalah faktor kunci bagi investor. Perubahan metrik ini dapat menunjukkan fundamental yang membaik atau memburuk, secara langsung memengaruhi harga saham. Di Eulerpool, Anda dapat melacak AxoGen EBITDA (Laba Sebelum Bunga, Pajak, Penyusutan & Amortisasi) secara historis dan real-time.

Access this data via the Eulerpool API

Laporan Laba Rugi — AxoGen

Semua Metrik Kunci — AxoGen